Claims
- 1. A method for diagnosing a neoplasm in a mammal, comprising measuring the level of helicase-like transcription factor (HLTF) in tissue of said mammal, wherein an increase in the level of HLTF in said tissue compared to the level in a normal control tissue indicates the presence of a neoplasm in said tissue.
- 2. The method of claim 1, wherein said measuring step comprises detecting a HLTF transcript in said tissue.
- 3. The method of claim 1, wherein said measuring step comprises detecting a HLTF gene product in said tissue.
- 4. The method of claim 1, wherein said tissue is breast tissue.
- 5. The method of claim 1, wherein said tissue is skin.
- 6. The method of claim 1, wherein said tissue is an HPV-containing lesion.
- 7. A method for detecting the presence of a malignant tumor or a predisposition to developing said tumor, comprising contacting a sample nucleic acid molecules obtained from a tissue biopsy with a nucleic acid probe which hybridizes under stringent conditions to a HLTF nucleic acid molecule and determining the level of binding of said probe, wherein an increase in said binding compared to a normal control level of binding indicates the presence of a malignant tumor or a predisposition to developing said tumor.
- 8. The method of claim 7, wherein said tissue is breast tissue.
- 9. The method of claim 7, wherein said tissue is skin.
- 10. The method of claim 7, wherein said tissue is an HPV-containing lesion.
- 11. A method of inhibiting carcinogenesis of a cell, comprising reducing the amount of HLTF in said cell, wherein a reduction in HLTF inhibits carcinogenesis.
- 12. The method of claim 11, wherein said method comprises contacting said cell with an HLTF antisense compound.
- 13. The method of claim 11, wherein said method comprises contacting said cell with an HLTF-specific antibody.
- 14. A method of inhibiting carcinogenesis of a cell, comprising contacting said cell with a compound which inhibits binding of endogenous HLTF to a telomerase reverse transcriptase (TERT) promoter.
- 15. The method of claim 14, wherein said compound is an oligonucleotide comprising a nucleotide sequence selected from the group consisting of ctgcc (SEQ ID NO:1), caccc (SEQ ID NO:2) ggcag (SEQ ID NO:3), agtgg (SEQ ID NO:4), ggcag (SEQ ID NO:5) agctgg (SEQ ID NO: 6), ggctg (SEQ ID NO:7).
- 16. The method of claim 14, wherein said compound is an oligonucleotide which binds to an hTERT promoter region comprising the nucleotide sequence of SEQ ID NO: (480 nt region of hTERT promoter).
- 17. The method of claim 14, wherein said compound is an polypeptide which binds to a nucleic acid comprising a nucleotide sequence selected from the group consisting of ctgcc (SEQ ID NO:1), caccc (SEQ ID NO:2) ggcag (SEQ ID NO:3), agtgg (SEQ ID NO:4), ggcag (SEQ ID NO:5) agctgg (SEQ ID NO:6), ggctg (SEQ ID NO:7).
- 18. The method of claim 14, wherein said compound is a polypeptide which binds to a nucleic acid comprising the nucleotide sequence of SEQ ID NO:8.
- 19. The method of claim 17, wherein said polypeptide is a fragment of HLTF.
- 20. A fragment of HLTF, wherein said fragment binds to an hTERT promoter region but does not transactivate hTERT promoter.
- 21. A fragment of HLTF, wherein said fragment does not bind to an hTERT promoter.
- 22. A method of inhibiting growth of a cell in an HPV-mediated hyperproliferative lesion, comprising reducing an amount of HLTF in said cell, wherein a reduction in HLTF inhibits growth said HPV-mediated hyperproliferative lesion.
- 23. The method of claim 22, wherein said method comprises contacting said cell with an HLTF antisense compound.
- 24. The method of claim 22, wherein said method comprises contacting said cell with a compound that inhibits binding of HLTF to a TERT promoter.
Parent Case Info
[0001] This application claims priority to provisional application U.S. S. No. 60/301,384, filed on Jun. 27, 2001, the entire contents of which is hereby incorporated by reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60301384 |
Jun 2001 |
US |